23andMe to Present at Upcoming Investor Conferences
23andMe Holding Co. (Nasdaq: ME), a leader in human genetics and biopharmaceuticals, announced participation in two upcoming investor conferences. The first is the Citi Healthcare Services, Medtech, Tools & HCIT Conference on March 1, 2023, at 9:30 a.m. ET in New York City. The second is the Cowen Health Care Conference on March 8, 2023, at 11:10 a.m. ET in Boston. Interested investors can access a live webcast of these presentations on the company’s investor website, with replays available shortly after each event. 23andMe aims to enhance understanding of the human genome through its genetic research.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be participating in investor presentations at the following conferences:
- Citi Healthcare Services, Medtech, Tools & HCIT Conference on Wednesday, March 1, 2023 at 9:30 a.m. ET in New York, NY
- Cowen Health Care Conference on Wednesday, March 8, 2023 at 11:10 a.m. ET in Boston, MA
Interested parties can access a live webcast of the presentations on the investors section of the Company website at investors.23andme.com under the “News & Events” menu. The latest information on this and other events, including any changes to presentation dates and times, can also be found there. A webcast replay will be available at the same location for a limited time within 24 hours after each event.
About 23andMe
23andMe is a genetics-led consumer healthcare and therapeutics company empowering a healthier future. For more information, please visit investors.23andme.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the future performance of 23andMe’s businesses in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding 23andMe’s strategy, financial position, funding for continued operations, cash reserves, projected costs, plans, and objectives of management, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "continue," "will," “schedule,” and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Except as required by law, 23andMe does not undertake any obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.
Investor Relations Contact: investors@23andMe.com
Media Contact: press@23andMe.com
FAQ
When is the Citi Healthcare Services Conference for 23andMe?
What is the date of the Cowen Health Care Conference for 23andMe?
How can I access the 23andMe investor presentations live?
Will there be a replay available for the 23andMe investor presentations?
